Patents by Inventor Bernard Lethe

Bernard Lethe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lage-1 tumor associated nucleic acids
    Patent number: 7998483
    Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: August 16, 2011
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
  • LAGE-1 TUMOR ASSOCIATED NUCLEIC ACIDS
    Publication number: 20090274716
    Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
    Type: Application
    Filed: July 14, 2009
    Publication date: November 5, 2009
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
  • LAGE-1 tumor associated nucleic acids
    Patent number: 7563870
    Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: July 21, 2009
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Bernard Lethé, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
  • MAGE-A1 peptides presented by HLA class II molecules
    Patent number: 7157091
    Abstract: The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0–10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: January 2, 2007
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jacques Van Snick, Bernard Lethé, Pascal Chaux, Thierry Boon-Falleur, Pierre van der Bruggen
  • LAGE-1 tumor associated nucleic acids
    Publication number: 20040234541
    Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
    Type: Application
    Filed: June 25, 2004
    Publication date: November 25, 2004
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
  • Lage-1 tumor associated nucleic acids
    Patent number: 6794131
    Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
    Type: Grant
    Filed: October 18, 1999
    Date of Patent: September 21, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
  • Mage-A3 peptides presented by HLA class molecules
    Patent number: 6716809
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
    Type: Grant
    Filed: September 15, 1999
    Date of Patent: April 6, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Erwin Schultz, Pascal Chaux, Jacques van Snick, Bernard Lethe, Thierry Boon-Fallaur, Pierre van der Bruggan, Vincent Stroobant, Kris Thielemans, Jurgen Corthals, Carlo Heirman
  • METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS
    Patent number: 6669946
    Abstract: The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: December 30, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethe
  • Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals
    Publication number: 20020128200
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Application
    Filed: December 11, 2001
    Publication date: September 12, 2002
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel, Bernard Lethe
  • Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals
    Patent number: 6284476
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: October 11, 1995
    Date of Patent: September 4, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethé
  • Isolated tyrosinase derived peptides and uses thereof
    Patent number: 5843688
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: January 5, 1996
    Date of Patent: December 1, 1998
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thomas Wolfel, Aline Van Pel, Vincent Brichard, Thierry Boon-Falleur, Etienne DePlaen, Pierre Coulie, Jean-Christophe Renauld, Bernard Lethe
  • LL-1 tumor specific genes
    Patent number: 5811519
    Abstract: The invention describes the LL-1 tumor specific gene family, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LL-1 gene product.
    Type: Grant
    Filed: January 27, 1997
    Date of Patent: September 22, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
  • Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3 gene products
    Patent number: 5763155
    Abstract: A method for determining lung adenocarcinomas is described. The method involves assaying for expression of a gene coding for at least one of tumor rejection antigen precursors MAGE-1, 2 and 3, or their expression product.
    Type: Grant
    Filed: May 10, 1996
    Date of Patent: June 9, 1998
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thierry Boon-Falleur, P. Weynants, Bernard Lethe, Francis Brasseur, M. Marchand, Charles DeSmet, Christophe Lurquin, Pierre Van Der Bruggen, Etienne DePlaen
  • Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
    Patent number: 5763165
    Abstract: A method for determining lung adenocarcinomas is described. The method involves assaying for expression of a gene coding for at least one of tumor rejection antigen precursors MAGE-1, 2 and 3, or their expression product.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: June 9, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Patrick Weynants, Bernard Lethe, Francis Brasseur, Marie Marchand, Charles DeSmet, Christophe Lurquin, Pierre van der Bruggen, Etienne DePlaen
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5744316
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: January 17, 1996
    Date of Patent: April 28, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Bernard Lethe, Vincent Brichard, Aline Van Pel, Thomas Wolfel, Thierry Boon-Falleur
  • Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
    Patent number: 5612201
    Abstract: The invention relates to nucleic acid molecules which are useful in determining expression of the family of molecules known as the MAGE tumor rejection antigen precursors. These nucleic acid are molecules useful as diagnostic aids for determining whether or not an individual has cancer. Methods using these molecules are also described.
    Type: Grant
    Filed: September 1, 1994
    Date of Patent: March 18, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Etienne De Plaen, Thierry Boon-Falleur, Bernard Lethe, Jean-Pierre Szikora, Charles De Smet, Patrick Chomez
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5530096
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: June 25, 1996
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thomas Wolfel, Aline Van Pel, Vincent Brichard, Thierry Boon-Falleur, Etienne DePlaen, Pierre Coulie, Jean-Christophe Renauld, Bernard Lethe
  • Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
    Patent number: 5512437
    Abstract: A method for determining head and neck squamous cell carcinomas, bladder tumors and prostate carcinomas is described. The method involves assaying for expression of the gene coding for tumor rejection antigen precursor MAGE-3, or its expression product. Various assays, and kits useful for these assays, are described.
    Type: Grant
    Filed: March 1, 1994
    Date of Patent: April 30, 1996
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Beatrice Gaugler, Thierry Boon-Falleur, Benoit van den Eynde, Etienne DePlaen, Francis Basseur, Bernard Lethe, Pierre van der Bruggen
  • Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
    Patent number: 5487974
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase-derived peptide having the amino acid sequence Met Leu Leu Ala Val Leu Tyr Cys Leu Leu. The invention further relates to the detection of these complexes on the surface of abnormal cells and, in particular, on the surface of melanoma cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: January 30, 1996
    Assignee: Ludwig Institute for Cancer-Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel, Bernard Lethe